Kyverna Therapeutics, Inc. (KYTX) Financials

KYTX Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 257.0 million 61.4 million
Dec. 31, 2025 293.8 million 61.6 million
Sept. 30, 2025 187.2 million 35.2 million
June 30, 2025 226.5 million 42.1 million

KYTX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -41.6 million 3.2 million
Dec. 31, 2025 -33.5 million 2.7 million
Sept. 30, 2025 -43.7 million 2.7 million
June 30, 2025 -32.2 million 2.5 million

KYTX Net Income

No data available :(

KYTX Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 236.4 million 7.0 million -
Dec. 31, 2025 279.3 million 24.7 million 320000
Sept. 30, 2025 171.1 million - 1.3 million
June 30, 2025 211.7 million - 5.9 million

KYTX Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 60.4 million
Dec. 31, 2025 47.2 million
Sept. 30, 2025 43.4 million
June 30, 2025 43.2 million

KYTX Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 29.7 million 11.3 million -
Dec. 31, 2025 5000 30.0 million 9.3 million -
Sept. 30, 2025 392000 30.5 million 8.3 million -
June 30, 2025 204000 35.8 million 8.6 million -

KYTX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 351000
Dec. 31, 2025 - 368000
Sept. 30, 2025 - 415000
June 30, 2025 - 515000

KYTX

Price: $7.92

52 week price:
2.52
13.67

Earnings Per Share: -3.27 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 342.5 million

Links: